Want to join the conversation?
$OREX 2Q15 Call: In 1H15, overall market was up 14% vs. 1H14. Now, overall market grew about 10% for 2014 vs. 2013. Branded market, including Xenical, Qsymia, Belviq, Contrave and Saxenda, was up about 101% for 1H15 vs. 1H14. In the long term, market has very strong potential given the low treatment penetration rates in huge unmet needs.
Still in yesterday’s $PZZA shock. I thought everyone had more pizza this football season!!
$TSLA stock downgraded to sell from hold by brokerage firm CFRA Research. However, the firm lifted the price target by $35 to $240.
$LB shares have plummeted after a disappointing quarter.